Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study

2018 Egger, 1997, Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study, BMJ, 315, 1194, 10.1136/bmj.315.7117.1194 May, 2010, Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes, Lancet, 376, 449, 10.1016/S0140-6736(10)60666-6 2007, Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries, Clin Infect Dis, 45, 1518, 10.1086/522986 Lawn, 2010, Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources, Lancet Infect Dis, 10, 489, 10.1016/S1473-3099(10)70078-5 Gupta, 2012, Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community, PLoS One, 7, e34156, 10.1371/journal.pone.0034156 Mariandyshev, 2017, Drug-resistant tuberculosis threatens WHO's End-TB strategy, Lancet Infect Dis, 17, 674, 10.1016/S1473-3099(17)30246-3 Gandhi, 2006, Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa, Lancet, 368, 1575, 10.1016/S0140-6736(06)69573-1 Klopper, 2013, Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa, Emerg Infect Dis, 19, 449, 10.3201/eid1903.120246 Lange, 2014, Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement, Eur Respir J, 44, 23, 10.1183/09031936.00188313 Horsburgh, 2015, Treatment of tuberculosis, N Engl J Med, 373, 2149, 10.1056/NEJMra1413919 Wright, 2009, Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance, Lancet, 373, 1861, 10.1016/S0140-6736(09)60331-7 Falzon, 2011, WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update, Eur Respir J, 38, 516, 10.1183/09031936.00073611 Köser, 2013, Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis, N Engl J Med, 369, 290, 10.1056/NEJMc1215305 Schon, 2017, Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives, Clin Microbiol Infect, 23, 154, 10.1016/j.cmi.2016.10.022 Boehme, 2010, Rapid molecular detection of tuberculosis and rifampin resistance, N Engl J Med, 363, 1005, 10.1056/NEJMoa0907847 Egger, 2012, Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, Int J Epidemiol, 41, 1256, 10.1093/ije/dyr080 McGowan, 2007, Cohort profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme, Int J Epidemiol, 36, 969, 10.1093/ije/dym073 2015 Harris, 2009, Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, 42, 377, 10.1016/j.jbi.2008.08.010 2014 2018 2014 Greenland, 1993, Maximum likelihood estimation of the attributable fraction from logistic models, Biometrics, 49, 865, 10.2307/2532206 Cox, 2018, Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?, Lancet Infect Dis, 18, e282, 10.1016/S1473-3099(18)30104-X 2011 Steingart, 2014, Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults, Cochrane Database Syst Rev, 1 Dheda, 2017, The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis, Lancet Respir Med, 5, 291, 10.1016/S2213-2600(17)30079-6 Sanker, 2017, Are WHO approved nucleic acid amplification tests causing large-scale ‘false identification’ of rifampicin-resistant tuberculosis? Programmatic experience from South India, Int J Mycobacteriology, 6, 21, 10.4103/2212-5531.201900 Chakravorty, 2017, The new Xpert MTB/RIF ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing, MBio, 8, e00812, 10.1128/mBio.00812-17 Rinder, 2001, Heteroresistance in Mycobacterium tuberculosis, Int J Tuberc Lung Dis, 5, 339 Cohen, 2012, Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control, Clin Microbiol Rev, 25, 708, 10.1128/CMR.00021-12 2016 Kim, 2005, Drug-susceptibility testing in tuberculosis: methods and reliability of results, Eur Respir J, 25, 564, 10.1183/09031936.05.00111304 Bastos, 2017, An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis, Eur Respir J, 49, 1600803, 10.1183/13993003.00803-2016 Mugabo, 2015, Do HIV infection and antiretroviral therapy influence multidrug-resistant tuberculosis treatment outcomes?, African J Pharm Pharmacol, 9, 875, 10.5897/AJPP2015.4298 Pietersen, 2014, Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study, Lancet, 383, 1230, 10.1016/S0140-6736(13)62675-6 Seung, 2010 van der Heijden, 2017, Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa, Int J Tuberc Lung Dis, 21, 670, 10.5588/ijtld.16.0843 Gegia, 2017, Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis, Lancet Infect Dis, 17, 223, 10.1016/S1473-3099(16)30407-8 2018 Gurumurthy, 2004, Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis, Clin Infect Dis, 38, 280, 10.1086/380795 Muller, 2010, Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis, Lancet Infect Dis, 10, 251, 10.1016/S1473-3099(10)70026-8 Burman, 1999, Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis, Clin Infect Dis, 28, 419, 10.1086/515174 Gopalan, 2016, Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis, AIDS Res Ther, 13, 34, 10.1186/s12981-016-0118-7 Meintjes, 2014, Management of drug-resistant TB in patients with HIV co-infection, J Int AIDS Soc, 17, 19508, 10.7448/IAS.17.4.19508 Gandhi, 2012, Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting, Int J Tuberc Lung Dis, 16, 90, 10.5588/ijtld.11.0153 Seung, 2009, Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa, PLoS One, 4, 2, 10.1371/journal.pone.0007186 Merker, 2013, Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients, PLoS One, 8, e82551, 10.1371/journal.pone.0082551 Miotto, 2017, A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis, Eur Respir J, 50, 1701354, 10.1183/13993003.01354-2017